Sotera Health CoSHC +1.01%74 3-Year ROIIC % is -85.65 as of Dec. 2025. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 82.76% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sotera Health Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -85.65%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sotera Health Co's 3-Year ROIIC % or its related term are showing as below:
SHC's 3-Year ROIIC % is ranked worse than 82.76% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs SHC: -85.65
Sotera Health Co (NAS:SHC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sotera Health Co 3-Year ROIIC % Related Terms
Sotera Health Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs VCYT, RDNT, BLLN: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sotera Health Co (SHC) has a 3-Year ROIIC % of -85.65 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sotera Health Co and its competitors. According to the industry distribution chart, Sotera Health Co ranks #168 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 82.8%.
Is Sotera Health Co's 3-Year ROIIC % too high?
Sotera Health Co's current 3-Year ROIIC % is -85.65. Based on the distribution chart, Sotera Health Co ranks #168 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's 3-Year ROIIC % compare to VCYT and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #168 out of 203 companies for 3-Year ROIIC %. This places Sotera Health Co in the lower half of its industry. The industry median 3-Year ROIIC % is 0.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current 3-Year ROIIC % is -85.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.33, compared to a current price of $17.93 — trading 9.8% above its estimated fair value. The current 3-Year ROIIC % is -85.65. Sotera Health Co's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sotera Health Co (SHC), the current 3-Year ROIIC % is -85.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.93 is trading 9.8% above its estimated GF Value™ of $16.33.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
3-Year ROIIC %: -85.65
GF Value™: $16.33 vs. price of $17.93 (9.8% above fair value)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
